



Foresee Pharmaceuticals Co., Ltd.

<http://www.ForeseePharma.com>

Company Description

Foresee is a Taiwan and US-based biopharmaceutical company listed on the Taipei Exchange. Foresee's R&D efforts are focused in two key areas, namely its unique stabilized injectable formulation delivery technology and derived drug products targeting specialty markets, and its first-in-class NCE programs targeting disease areas with high unmet needs.

Product / Service:

Foresee's product portfolio includes late stage and early stage programs such as FP-001, stable, ready-to-use, regulatory submissions are planned in 2019; FP-025, a MMP-12 inhibitor targeting inflammatory and fibrotic diseases, currently in a P2 POC study; FP-045, an ALDH2 activator, a P1b/P2 study is currently in planning Fanconi Anemia, mitochondrial-mediated diseases.

Contact Information

Name	Mathieu Boudreau An Chung	Position Vice President, Business Development Public Relations/ Investor Relations
Tel	+886-2-7750 0188	
E-mail	Mathieu.Boudreau@foreseepharma.com An.Chung@foreseepharma.com	
Address	9F-2, No.19-3, Sanchong Rd., Nangang Dist., Taipei City, Taiwan (R.O.C.)	
Sectors	Drug Development and Repurposing	